Meglitinides drug class for Type 2 diabetes treatment include repaglinide (Prandin) and nateglinide (Starlix) as oral diabetic medications. High fasting insulin levels and a reduction in insulin action may be present in person with Type 2 diabetes symptoms but so is absent or blunted first-phase insulin response to a meal. Most sulfonylureas (except Amaryl glimepiride) increase pancreatic beta-cell insulin secretion as well as plasma insulin concentration in people with Type 2 diabetes symptoms. But sulfonylureas oral diabetic medications fail to improve first-phase insulin release. Here comes meglitinides for Type 2 diabetes treatment. Starlix (nateglinide) and Prandin (repaglinide) as oral diabetic medications do increase first-phase insulin response, allowing to control sugar levels in blood after a meal. Both Starlix 60 mg pills and Prandin 1 mg pills are rapid-acting insulin secretagogues. When Prandin or Starlix meglitinides are taken 15 to 20 minutes before a meal, postprandial glucose excersions can be contained and minimized by this oral diabetic medications. This is important because high glucose level after a meal has been linked to cardiovascular diabetic complication.